| P50 | author | Faramarz Ismail-Beigi | Q98918532 |
| P2093 | author name string | Manuel Lombardero | |
| | Saul Genuth | |
| | Joel Zonszein | |
| | Pasquale Palumbo | |
| | Gary Cushing | |
| | Bari 2D Study Group | |
| | Bernardo Wajchenberg | |
| | Suzy Foucher | |
| | Yolanda Groenewoud | |
| P2860 | cites work | Prevalence and identification of abnormal lipoprotein levels in a biracial population aged 23 to 35 years (the CARDIA Study). The Coronary Artery Risk Development in Young Adults Study. | Q51016459 |
| | U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | Q56914456 |
| | Changes in diabetes-related complications in the United States, 1990-2010 | Q64125961 |
| | (7) Approaches to glycemic treatment | Q86396528 |
| | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 |
| | Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 |
| | Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial | Q30438736 |
| | A randomized trial of therapies for type 2 diabetes and coronary artery disease | Q33827504 |
| | Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. | Q33901958 |
| | Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis | Q34142893 |
| | Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 |
| | Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 |
| | The global spread of type 2 diabetes mellitus in children and adolescents. | Q36116070 |
| | Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. | Q36297873 |
| | Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? | Q36539179 |
| | Type 2 diabetes in youth: epidemiology and pathophysiology | Q36783734 |
| | Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). | Q37022623 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease | Q38250379 |
| | Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. | Q41275648 |
| | Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know | Q42362563 |
| | The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease | Q43109231 |
| | Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant | Q44659546 |
| | Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? | Q45266146 |
| | Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations | Q45931171 |
| | Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans | Q46458608 |
| | Ethnic differences in the ability of triglyceride levels to identify insulin resistance | Q46751189 |
| | Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant | Q47972709 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | preproinsulin | Q7240673 |
| | triglyceride | Q186319 |
| | type 2 diabetes | Q3025883 |
| P304 | page(s) | 129891 | |
| P577 | publication date | 2015-05-27 | |
| P1433 | published in | Journal of Diabetes Research | Q26841822 |
| P1476 | title | Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. | |
| P478 | volume | 2015 | |